4. Bliss GVS Pharma Limited (NSE:BLISSGVS)
Existing Pharmaceutical Earnings Offer a Different Growth Route
Bliss GVS Pharma Limited (NSE: BLISSGVS) brings pharmaceutical manufacturing and marketed products to a watchlist otherwise heavily influenced by clinical development.
For the quarter ended June 30, 2026, its exchange filing reported standalone revenue from operations of approximately ₹221.6 crore and net profit of ₹38.6 crore. Those figures refer to the standalone company, rather than consolidated group results, an important distinction when assessing its full financial performance.
The attraction is an established revenue base. Investors can assess manufacturing profitability, operating expenses, and cash conversion instead of relying entirely on a future drug approval.
However, accounting profit needs to be supported by collections. Working-capital requirements, receivables, manufacturing compliance, and product pricing deserve attention when evaluating whether earnings can finance further growth.
Its reported market capitalization was roughly ₹7,010 crore on October 16, making the micro-cap label inappropriate without a clearly stated local classification framework.
Ranking rationale
Bliss earns fourth place because its existing sales and profitability provide an operating foundation for further growth. Its position remains below the biotechnology selections because this watchlist gives greater weight to identifiable clinical and commercial developments, while its consolidated performance and cash conversion require closer examination.
